Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia AFunding This work was funded by Novo Nordisk A/S (Bagsværd, Denmark). Novo Nordisk's policy on data sharing may be found at https://www.novonordisk-trials.com/how-access-clinical-trial-datasets.
13 May 2019
19 October 2019
30 December 2019 (online)
Background Factor VIII (FVIII) products are usually dosed according to body weight (BW). This may lead to under- or over-dosing in underweight or obese patients, respectively.
Objective This article evaluates the pharmacokinetics (PK) of recombinant FVIII concentrate, particularly recovery, in relation to body mass index (BMI) and other body composition descriptors.
Materials and Methods Thirty-five previously treated adults with severe haemophilia A from five BMI categories (underweight, normal, overweight, obese class I and II/III) were included. PK was evaluated after 50 IU per kilogram of BW single-dose recombinant FVIII (turoctocog alfa). The body composition variable was based on measurements of weight, height, bioimpedance analysis, and dual-energy X-ray absorptiometry. A dosing model was derived to achieve similar peak FVIII activity levels across BMI categories.
Results A statistically significant positive association between BMI and C30min, IR30min, and AUC0–inf was observed; CL and Vss showed a significant negative association with BMI; t½ was independent of BMI and other parameters. The dosing model introduced a correction factor ‘M’ for each BMI category, based on linear regression analysis of C30min against BMI, which ranged from 0.55 for underweight to 0.39 for obese class II/III. This model achieved similar peak FVIII activity levels across BMI categories, estimating an average dose adjustment of +243.3 IU (underweight) to –1,489.6 IU (obese class II/III) to achieve similar C30min.
Conclusion BMI appears to be the best predictor of recombinant FVIII recovery; however, PK endpoints were also dependent on other body composition variables. The model demonstrated that dosing can be adjusted for individual BMI to achieve better FVIII predictability across BMI categories.
All authors confirm they have had full access to the data and contributed to the drafting of this manuscript.
- 1 Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40 (11) 815-832
- 2 Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. J Thromb Haemost 2011; 9 (09) 1784-1790
- 3 McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis. Pharmaceutics 2017; 9 (04) E47
- 4 Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 362-368
- 5 Tuinenburg A, Biere-Rafi S, Peters M. , et al. Obesity in haemophilia patients: effect on bleeding frequency, clotting factor concentrate usage, and haemostatic and fibrinolytic parameters. Haemophilia 2013; 19 (05) 744-752
- 6 Wong TE, Majumdar S, Adams E. , et al; Healthy Weight Working Group. Overweight and obesity in hemophilia: a systematic review of the literature. Am J Prev Med 2011; 41 (06) (Suppl. 04) S369-S375
- 7 Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977; 56 (4 Pt 1): 605-612
- 8 Björkman S, Blanchette VS, Fischer K. , et al; Advate Clinical Program Group. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8 (04) 730-736
- 9 Blanchette VS, Shapiro AD, Liesner RJ. , et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6 (08) 1319-1326
- 10 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. ; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (01) 2-10
- 11 Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica 2013; 98 (09) 1481-1486
- 12 Kepa S, Horvath B, Reitter-Pfoertner S. , et al. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia 2015; 21 (03) 343-350
- 13 Zupančić-Šalek S, Ozelo MC, Korsholm L. , et al. An evaluation of the pharmacokinetics of turoctocog alfa in relation to body mass index (BMI) in patients with haemophilia A (HA). Res Pract Thromb Haemost 2017; 1 (01) 671
- 14 World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310 (20) 2191-2194
- 15 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1); 1996. Available at: http://apps.who.int/medicinedocs/documents/s22154en/s22154en.pdf . Accessed November 17, 2019
- 16 Kulkarni R, Karim FA, Glamocanin S. , et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19 (05) 698-705
- 17 Lentz SR, Misgav M, Ozelo M. , et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19 (05) 691-697
- 18 Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989; 5 (05) 303-311
- 19 Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44 (10) 1051-1065
- 20 Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg 2006; 16 (06) 773-776
- 21 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
- 22 NovoEight® Summary of Product Characteristics. Novo Nordisk A/S, Bagsværd, Denmark. Available at: https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf . Accessed July 9, 2019
- 23 Henrard S, Hermans C. Impact of being overweight on factor VIII dosing in children with haemophilia A. Haemophilia 2016; 22 (03) 361-367
- 24 Lee SY, Ahn S, Kim YJ. , et al. Comparison between dual-energy X-ray absorptiometry and bioelectrical impedance analyses for accuracy in measuring whole body muscle mass and appendicular skeletal muscle mass. Nutrients 2018; 10 (06) pii: E738
- 25 Singer JP, Peterson ER, Snyder ME. , et al. Body composition and mortality after adult lung transplantation in the United States. Am J Respir Crit Care Med 2014; 190 (09) 1012-1021
- 26 Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010: 802078
- 27 Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007; 27 (05) 996-1003
- 28 Lalezari S, Martinowitz U, Windyga J. , et al. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia 2014; 20 (01) e15-e22
- 29 Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87 (Suppl. 01) S33-S39
- 30 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10) 989-998
- 31 Björkman S, Oh M, Spotts G. , et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119 (02) 612-618
- 32 Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. Haemophilia 2015; 21 (02) 204-209